Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 133
Filter
1.
Oncotarget ; 7(30): 48533-48546, 2016 Jul 26.
Article in English | MEDLINE | ID: mdl-27391430

ABSTRACT

p63 is a structural homolog within the 53 family encoding two isoforms, ΔNp63 and TAp63. The oncogenic activity of ΔNp63 has been demonstrated in multiple cancers, however the underlying mechanisms that contribute to tumorigenesis are poorly characterized. Osteosarcoma (OSA) is the most common primary bone tumor in dogs, exhibiting clinical behavior and molecular biology essentially identical to its human counterpart. The purpose of this study was to evaluate the potential contribution of ΔNp63 to the biology of canine OSA. As demonstrated by qRT-PCR, nearly all canine OSA cell lines and tissues overexpressed ΔNp63 relative to normal control osteoblasts. Inhibition of ΔNp63 by RNAi selectively induced apoptosis in the OSA cell lines overexpressing ΔNp63. Knockdown of ΔNp63 upregulated expression of the proapoptotic Bcl-2 family members Puma and Noxa independent of p53. However the effects of ΔNp63 required transactivating isoforms of p73, suggesting that ΔNp63 promotes survival in OSA by repressing p73-dependent apoptosis. In addition, ΔNp63 modulated angiogenesis and invasion through its effects on VEGF-A and IL-8 expression, and STAT3 phosphorylation. Lastly, the capacity of canine OSA cell lines to form pulmonary metastasis was directly related to expression levels of ΔNp63 in a murine model of metastatic OSA. Together, these data demonstrate that ΔNp63 inhibits apoptosis and promotes metastasis, supporting continued evaluation of this oncogene as a therapeutic target in both human and canine OSA.


Subject(s)
Bone Neoplasms/pathology , Lung Neoplasms/pathology , Osteosarcoma/pathology , STAT3 Transcription Factor/metabolism , Sarcoma, Experimental/pathology , Transcription Factors/metabolism , Tumor Suppressor Proteins/metabolism , Animals , Apoptosis , Bone Neoplasms/veterinary , Cell Line, Tumor , Cell Survival , Dogs , Female , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Interleukin-8/metabolism , Lung Neoplasms/secondary , Mice , Mice, SCID , Neoplasm Invasiveness/pathology , Neovascularization, Pathologic/pathology , Osteoblasts , Osteosarcoma/veterinary , Phosphorylation , Protein Isoforms/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , RNA Interference , RNA, Small Interfering/metabolism , Sarcoma, Experimental/secondary , Transcription Factors/genetics , Tumor Protein p73/metabolism , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/genetics , Vascular Endothelial Growth Factor A/metabolism
2.
Mol Cancer Res ; 11(10): 1235-47, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23938949

ABSTRACT

UNLABELLED: Comparing the gene expression profiles of metastatic and nonmetastatic cells has the power to reveal candidate metastasis-associated genes, whose involvement in metastasis can be experimentally tested. In this study, differentially expressed genes were explored in the v-src-transformed metastatic cell line PR9692 and its nonmetastatic subclone PR9692-E9. First, the contribution of homeodomain only protein X (HOPX) in metastasis formation and development was assessed. HOPX-specific knockdown decreased HOPX expression in the nonmetastatic subclone and displayed reduced cell motility in vitro. Critically, HOPX knockdown decreased the in vivo metastatic capacity in a syngeneic animal model system. Genomic analyses identified a cadre of genes affected by HOPX knockdown that intersected significantly with genes previously found to be differentially expressed in metastatic versus nonmetastatic cells. Furthermore, 232 genes were found in both screens with at least a two-fold change in gene expression, and a number of high-confidence targets were validated for differential expression. Importantly, significant changes were demonstrated in the protein expression level of three metastatic-associated genes (NCAM, FOXG1, and ITGA4), and knockdown of one of the identified HOPX-regulated metastatic genes, ITGA4, showed marked inhibition of cell motility and metastasis formation. These data demonstrate that HOPX is a metastasis-associated gene and that its knockdown decreases the metastatic activity of v-src-transformed cells through altered gene expression patterns. IMPLICATIONS: This study provides new mechanistic insight into a HOPX-regulated metastatic dissemination signature.


Subject(s)
Avian Proteins/genetics , Forkhead Transcription Factors/metabolism , Homeodomain Proteins/genetics , Neoplasm Metastasis/genetics , Neural Cell Adhesion Molecules/metabolism , Sarcoma, Experimental/genetics , Animals , Avian Proteins/metabolism , Cell Cycle , Cell Line, Tumor , Cell Movement , Cell Transformation, Neoplastic/genetics , Chickens , Down-Regulation , Forkhead Transcription Factors/genetics , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Genes, src , Homeodomain Proteins/metabolism , Neural Cell Adhesion Molecules/genetics , Oligonucleotide Array Sequence Analysis , Sarcoma, Experimental/pathology , Sarcoma, Experimental/secondary
3.
Am J Pathol ; 182(6): 2015-27, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23708211

ABSTRACT

Soft tissue sarcomas are a heterogeneous group of tumors associated with poor clinical outcome. Although a subset of soft tissue sarcomas is characterized by simple karyotypes and recurrent chromosomal translocations, the mechanisms driving cytogenetically complex sarcomas are largely unknown. Clinical evidence led us to partially inactivate Pten and Tp53 in the smooth muscle lineage of mice, which developed high-grade undifferentiated pleomorphic sarcomas, leiomyosarcomas, and carcinosarcomas that widely recapitulate the human disease, including the aberrant karyotype and metastatic behavior. Pten was found haploinsufficient, whereas the wild-type allele of Tp53 invariably gained point mutations. Gene expression profiles showed up-regulated Notch signaling in Pten(Δ/+)Tp53(Δ/+) tumors compared with Pten(+/+)Tp53(Δ/+) tumors. Consistently, Pten silencing exacerbated the clonogenic and invasive potential of Tp53-deficient bone marrow-derived mouse mesenchymal stem cells and tumor cells and activated the Notch pathway. Moreover, the increased oncogenic behavior of Pten(Δ/+)Tp53(Δ/+) and shPten-transduced Pten(+/+)Tp53(Δ/+) tumor cells was counteracted by treatment with a γ-secretase inhibitor, suggesting that the aggressiveness of those tumors can be attributed, at least in part, to enhanced Notch signaling. This study demonstrates a cooperative role for Pten and Tp53 suppression in complex karyotype sarcomas while establishing Notch as an important functional player in the cross talk of these pathways during tumor progression. Our results highlight the importance of molecularly subclassifying patients with high-grade sarcoma for targeted treatments.


Subject(s)
Genes, p53 , PTEN Phosphohydrolase/genetics , Receptors, Notch/metabolism , Sarcoma/genetics , Soft Tissue Neoplasms/genetics , Animals , DNA Mutational Analysis/methods , Disease Progression , Down-Regulation/physiology , Gene Deletion , Genotype , Haploinsufficiency , Humans , Leiomyosarcoma/genetics , Leiomyosarcoma/metabolism , Leiomyosarcoma/secondary , Mesenchymal Stem Cells/metabolism , Mice , Mice, Knockout , Neoplasm Invasiveness , Neoplastic Stem Cells/metabolism , PTEN Phosphohydrolase/biosynthesis , Sarcoma/metabolism , Sarcoma, Experimental/genetics , Sarcoma, Experimental/metabolism , Sarcoma, Experimental/pathology , Sarcoma, Experimental/secondary , Signal Transduction/physiology , Soft Tissue Neoplasms/metabolism , Tumor Suppressor Proteins/biosynthesis , Tumor Suppressor Proteins/genetics
4.
J Vis Exp ; (45)2010 Nov 26.
Article in English | MEDLINE | ID: mdl-21178954

ABSTRACT

Experimental metastasis mouse model is a simple and yet physiologically relevant metastasis model. The tumor cells are injected intravenously (i.v) into mouse tail veins and colonize in the lungs, thereby, resembling the last steps of tumor cell spontaneous metastasis: survival in the circulation, extravasation and colonization in the distal organs. From a therapeutic point of view, the experimental metastasis model is the simplest and ideal model since the target of therapies is often the end point of metastasis: established metastatic tumor in the distal organ. In this model, tumor cells are injected i.v into mouse tail veins and allowed to colonize and grow in the lungs. Tumor-specific CTLs are then injected i.v into the metastases-bearing mouse. The number and size of the lung metastases can be controlled by the number of tumor cells to be injected and the time of tumor growth. Therefore, various stages of metastasis, from minimal metastasis to extensive metastasis, can be modeled. Lung metastases are analyzed by inflation with ink, thus allowing easier visual observation and quantification.


Subject(s)
Disease Models, Animal , Immunotherapy, Adoptive/methods , Lung Neoplasms/secondary , Lung Neoplasms/therapy , T-Lymphocytes, Cytotoxic/immunology , Animals , Female , Lung Neoplasms/immunology , Mammary Neoplasms, Experimental/immunology , Mammary Neoplasms, Experimental/pathology , Mammary Neoplasms, Experimental/therapy , Mice , Neoplasm Transplantation , Sarcoma, Experimental/immunology , Sarcoma, Experimental/pathology , Sarcoma, Experimental/secondary , Sarcoma, Experimental/therapy
5.
J Bone Joint Surg Br ; 92(4): 580-5, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20357339

ABSTRACT

We undertook a study of the anti-tumour effects of hyperthermia, delivered via magnetite cationic liposomes (MCLs), on local tumours and lung metastases in a mouse model of osteosarcoma. MCLs were injected into subcutaneous osteosarcomas (LM8) and subjected to an alternating magnetic field which induced a heating effect in MCLs. A control group of mice with tumours received MCLs but were not exposed to an AMF. A further group of mice with tumours were exposed to an AMF but had not been treated with MCLs. The distribution of MCLs and local and lung metastases was evaluated histologically. The weight and volume of local tumours and the number of lung metastases were determined. Expression of heat shock protein 70 was evaluated immunohistologically. Hyperthermia using MCLs effectively heated the targeted tumour to 45 degrees C. The mean weight of the local tumour was significantly suppressed in the hyperthermia group (p = 0.013). The mice subjected to hyperthermia had significantly fewer lung metastases than the control mice (p = 0.005). Heat shock protein 70 was expressed in tumours treated with hyperthermia, but was not found in those tumours not exposed to hyperthermia. The results demonstrate a significant effect of hyperthermia on local tumours and reduces their potential to metastasise to the lung.


Subject(s)
Ferrosoferric Oxide/administration & dosage , Hyperthermia, Induced/methods , Osteosarcoma/therapy , Sarcoma, Experimental/therapy , Animals , HSP70 Heat-Shock Proteins/metabolism , Liposomes , Lung Neoplasms/prevention & control , Lung Neoplasms/secondary , Male , Metal Nanoparticles/administration & dosage , Mice , Mice, Inbred C3H , Necrosis , Osteosarcoma/pathology , Osteosarcoma/secondary , Sarcoma, Experimental/pathology , Sarcoma, Experimental/secondary , Skin Temperature
6.
Int J Exp Pathol ; 90(1): 44-51, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19200250

ABSTRACT

The tumour microenvironment, which is largely composed of inflammatory cells, is a crucial participant in the neoplastic process through the promotion of cell proliferation, survival and migration. Neutrophil polymorphonuclear cells (PMNs) induce inflammatory reactions that can be either cytotoxic for tumour cells or can promote tumour growth and metastasis. Previously, we have reported a spontaneous metastasis tumour model that has tumour PMNs infiltration, and metastasis, to liver and spleen. The aim of this study was to evaluate the PMNs influences on the tumour cell invasion and metastatic properties. We analysed intercellular adhesion molecule-1 (ICAM-1), urokinase-type plasminogen activator receptor (uPAR), MT1-MMP (membrane type 1-matrix metalloproteinase) and MMP2 protein expression in TuE-t cells cultured with PMNs or PMNs-conditioned medium isolated from tumour bearing and normal rats. The interaction between tumour cells and PMNs induced a decrease in ICAM-1 expression in tumour cells as well as an increase in MMP2 and tumour cell motility. Besides, conserved expression of uPAR and MT1-MMP in tumour cells was also demonstrated. The up-regulation in MMP2 associated with uPAR and MT1-MMP conserved expression may be related to an increased extracellular matrix proteolysis. These results showed that the interaction of tumour cells with PMNs could favour tumour cell spreading through the promotion of a tumour invasive phenotype.


Subject(s)
Neutrophils/physiology , Sarcoma, Experimental/secondary , Animals , Cell Adhesion/drug effects , Cell Line, Tumor , Cell Movement/physiology , Culture Media, Conditioned/pharmacology , Female , Intercellular Adhesion Molecule-1/metabolism , Matrix Metalloproteinase 14/metabolism , Matrix Metalloproteinase 2/metabolism , Neoplasm Invasiveness , Neoplasm Proteins/metabolism , Neoplasm Transplantation , Rats , Rats, Wistar , Receptors, Urokinase Plasminogen Activator/metabolism , Sarcoma, Experimental/pathology , Wound Healing/physiology
8.
Anticancer Res ; 23(5A): 3713-8, 2003.
Article in English | MEDLINE | ID: mdl-14666668

ABSTRACT

BACKGROUND: Intraoperative pleural and interstitial PDT accompanying resection may reduce peripheral micrometastatic foci and preclude lobectomy when applied to hilar lesions. MATERIALS AND METHODS: Fourteen beagles were used to determine the safety and histologic changes resulting from PDT. Photosensitizers HPPH (0.3 mg/kg) or Photofrin (2.0 mg/kg) were administered i.v. 48 hours prior to thoracotomy and light delivery. At thoracotomy interstitial or pleural light was given. They underwent necropsy at eight and 30 days. RESULTS: The significant toxicitities occurred with pleural PDT using high dose HPPH (15 & 30 J/cm2) including pyrexia, elevated WBC and CPK, and respiratory distress. However, using single beam pleural surface treatment all light doses for HPPH and Photofrin (5-40 J/cm2) were tolerated with depths of treatment effect up to 10 mm with HPPH. CONCLUSION: Histologic and clinical changes associated with interstitial and pleural PDT were acceptable after dosimetry was adjusted. PDT holds promise as an adjuvant treatment for sarcoma pulmonary metastases.


Subject(s)
Chlorophyll/analogs & derivatives , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Photochemotherapy/adverse effects , Sarcoma, Experimental/drug therapy , Sarcoma, Experimental/secondary , Animals , Chlorophyll/adverse effects , Chlorophyll/therapeutic use , Dihematoporphyrin Ether/adverse effects , Dihematoporphyrin Ether/therapeutic use , Dogs , Hemorrhage/chemically induced , Lung Diseases/chemically induced , Lung Neoplasms/pathology , Photochemotherapy/methods , Photosensitizing Agents/adverse effects , Photosensitizing Agents/therapeutic use , Pleura/pathology , Sarcoma, Experimental/pathology
9.
J Immunol ; 171(5): 2402-12, 2003 Sep 01.
Article in English | MEDLINE | ID: mdl-12928387

ABSTRACT

The mechanisms of CTL-mediated tumor regression in vivo remain to be fully understood. If CTL do mediate tumor regression in vivo by direct cytotoxicity, this may occur via two major effector mechanisms involving the secretion of perforin/granzymes and/or engagement of Fas by Fas ligand (FasL) expressed by the activated CTL. Although the perforin pathway has been considered the dominant player, it is unclear whether Fas-mediated cytotoxicity is additionally required for optimal tumor rejection. Previously, we produced H-2L(d)-restricted CTL reactive against the CMS4 sarcoma, which expresses a naturally occurring rejection Ag recognized by these CTL and harbors a cytokine (IFN-gamma plus TNF)-inducible, Fas-responsive phenotype. The adoptive transfer of these CTL to syngeneic BALB/c mice with minimal (day 3 established) or extensive (day 10 established) experimental pulmonary metastases resulted in strong antitumor responses. Here we investigated whether a FasL-dependent CTL effector mechanism was important for optimal tumor regression in this adoptive immunotherapy model. The approach taken was to compare the therapeutic efficacy of wild-type to FasL-deficient (gld) CTL clones by adoptive transfer. In comparison with wild-type CTL, gld-CTL efficiently mediated tumor cytolysis and produced comparable amounts of IFN-gamma, after tumor-specific stimulation, as in vitro assessments of Ag recognition. Moreover, gld-CTL mediated comparably potent antitumor effects in a minimal disease setting, but were significantly less effective under conditions of an extensive tumor burden. Overall, under conditions of extensive lung metastases, these data revealed for the first time an important role for a FasL-dependent CTL effector mechanism in optimal tumor regression.


Subject(s)
Immunotherapy, Adoptive/methods , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Membrane Glycoproteins/physiology , Sarcoma, Experimental/therapy , Signal Transduction/immunology , T-Lymphocytes, Cytotoxic/transplantation , fas Receptor/physiology , Animals , Cell Line, Tumor , Clone Cells , Cytotoxicity, Immunologic/genetics , Disease Models, Animal , Fas Ligand Protein , Female , Injections, Intravenous , Ligands , Lung Neoplasms/genetics , Lung Neoplasms/immunology , Lymphocyte Activation/genetics , Membrane Glycoproteins/deficiency , Membrane Glycoproteins/genetics , Mice , Mice, Inbred BALB C , Mice, Transgenic , Neoplasm Transplantation , Perforin , Pore Forming Cytotoxic Proteins , Sarcoma, Experimental/genetics , Sarcoma, Experimental/immunology , Sarcoma, Experimental/secondary , Signal Transduction/genetics , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism , fas Receptor/biosynthesis
10.
J Immunol ; 170(12): 5973-80, 2003 Jun 15.
Article in English | MEDLINE | ID: mdl-12794124

ABSTRACT

Dysregulation of the Fas pathway has been implicated in tumor progression; however, how alterations in Fas expression influence metastatic behavior remains unresolved. In this study, we investigated the link between Fas expression and metastatic capacity in two mouse tumor models: one was a sarcoma, which was used to analyze the consequences of loss of Fas function in experimental pulmonary metastases, and the other was a mammary carcinoma, where Fas expression was examined in matched pairs of primary and metastatic cell lines as well as by immunohistochemistry of tissues taken from primary and metastatic sites of spontaneous tumor development. In the sarcoma model, a Fas-resistant/refractory subline was produced in vitro from the parental line by biologic selection against Fas-responsive cells, and it was then compared with the poorly metastatic parental line and to an in vivo-derived subline that was highly metastatic for growth in the lungs. In both tumor models, an inverse correlation was demonstrated between Fas expression and metastatic phenotype. Subsequent studies in the sarcoma model revealed that although the Fas-resistant/refractory subline displayed significant metastatic ability, the parental line from which it was derived exhibited little to no additional metastatic activity if experimentally rendered Fas-resistant by molecular-based strategies or transplanted into a Fas ligand-deficient host. Therefore, these findings suggested that down-regulation of Fas was associated with the metastatic phenotype, but alterations in Fas expression alone were insufficient for acquisition of full metastatic potential. Rather, the ability of such Fas-resistant neoplastic subpopulations to achieve metastatic competence apparently required co-possession of additional malignant characteristics.


Subject(s)
Adjuvants, Immunologic/biosynthesis , Adjuvants, Immunologic/genetics , Gene Expression Regulation, Neoplastic/immunology , Lung Neoplasms/immunology , Lung Neoplasms/secondary , Sarcoma, Experimental/secondary , fas Receptor/biosynthesis , fas Receptor/genetics , Adjuvants, Immunologic/metabolism , Adjuvants, Immunologic/physiology , Animals , Apoptosis/genetics , Apoptosis/immunology , Carcinoma/genetics , Carcinoma/immunology , Carcinoma/pathology , Carcinoma/secondary , Disease Progression , Fas Ligand Protein , Female , Ligands , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Mammary Neoplasms, Experimental/genetics , Mammary Neoplasms, Experimental/immunology , Mammary Neoplasms, Experimental/pathology , Membrane Glycoproteins/genetics , Membrane Glycoproteins/physiology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Transgenic , Neoplasm Transplantation/immunology , Phenotype , Sarcoma, Experimental/genetics , Sarcoma, Experimental/immunology , Sarcoma, Experimental/pathology , Tumor Cells, Cultured , fas Receptor/metabolism , fas Receptor/physiology
11.
Clin Exp Metastasis ; 20(2): 181-5, 2003.
Article in English | MEDLINE | ID: mdl-12705639

ABSTRACT

Metastasis to the lung is often a lethal event in sarcoma as well as other cancers. We report here a new animal model of sarcoma enabling the external real-time fluorescence imaging of spontaneous lung metastasis. The human fibrosarcoma cell line HT-1080 was transduced with the green fluorescent protein (GFP) gene. HT-1080-GFP cells were injected into the right hind footpad of severe combined immunodeficient (SCID) mice. The lung metastases were evaluated by whole-body fluorescence imaging as well as direct-view imaging in live animals through a skin-flap window over the chest wall. Spontaneous lung metastases were observed on the lungs of 11 of 12 mice. SCID mice well tolerated the skin-flap procedure enabling real-time imaging of spontaneous lung metastases with a resolution of approximately 50-100 microm. This procedure enabled external imaging at the micrometastasis level. Real-time evaluation of spontaneous lung metastasis in the same animals should allow drug evaluation and mechanistic studies not previously possible.


Subject(s)
Indicators and Reagents/metabolism , Luminescent Proteins/metabolism , Lung Neoplasms/metabolism , Lung Neoplasms/secondary , Sarcoma, Experimental/metabolism , Sarcoma, Experimental/secondary , Soft Tissue Neoplasms/pathology , Animals , Cell Division , Female , Green Fluorescent Proteins , Humans , Luminescent Proteins/genetics , Mice , Mice, SCID , Microscopy, Fluorescence , Plasmids , Retroviridae/genetics , Transfection , Tumor Cells, Cultured
12.
Cancer Res ; 63(5): 1040-5, 2003 Mar 01.
Article in English | MEDLINE | ID: mdl-12615720

ABSTRACT

The role of CD4+ T lymphocytes in antitumor immunity has been largely attributed to providing signals required for the priming of MHC class I-restricted CD8+ cytotoxic T lymphocytes, and CD8+ cytotoxic T lymphocytes are thought to serve as the predominant mediators of tumor killing in vivo. We decided to evaluate the role of T lymphocyte subsets in tumor immunity induced by recombinant SV40 large tumor antigen (Tag) within an experimental murine pulmonary metastasis model of SV40 Tag-expressing tumors. Studies in BALB/c mice used in vivo depletion of either CD4+ or CD8+ T cells in the induction phase of the immune response to SV40 Tag. These studies indicate that CD4+ T cells but not CD8+ T cells were critical in the production of antibodies to SV40 Tag and in tumor immunity as the result of recombinant SV40 Tag immunization. On the basis of the predominance of the IgG1 isotype in the antibody response to SV40 Tag immunization, Th2 type CD4+ T cells appeared to be involved. SV40 Tag immunization was not as effective in the induction of tumor immunity in therapeutic modalities when compared with the prophylactic setting. Our results suggest that CD4+ T cells, along with antibody responses, play a role in the induction of tumor immunity to a viral-encoded tumor antigen.


Subject(s)
Antibodies, Neoplasm/biosynthesis , Antigens, Polyomavirus Transforming/immunology , CD4-Positive T-Lymphocytes/immunology , Fibrosarcoma/immunology , Sarcoma, Experimental/immunology , Animals , Antibodies, Neoplasm/immunology , CD8-Positive T-Lymphocytes/immunology , Cell Line, Transformed , Fibrosarcoma/secondary , Fibrosarcoma/therapy , Immunization , Immunoglobulin G/biosynthesis , Immunoglobulin G/immunology , Lung Neoplasms/immunology , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Mice , Mice, Inbred BALB C , Sarcoma, Experimental/secondary , Sarcoma, Experimental/therapy , Simian virus 40/immunology , Th2 Cells/immunology
13.
Jpn J Cancer Res ; 93(10): 1090-9, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12417038

ABSTRACT

We investigated the mechanism of the enhancement of metastatic potential induced by transfection of the fyn gene, a member of the src family. We employed two murine fyn cDNA-transfected clones, ML-SN1 and ML-SN2, which were previously established from an ML-01 low-metastatic clone of Meth A sarcoma of BALB / c mice and were proven to have higher metastatic ability than ML-01 and the mock-transfected clone ML-MT-neo (Takayama et al., 1993). Our present investigation revealed that the two transfectants showed higher metastatic ability and higher rates of adherence to type IV collagen than ML-MT-neo. However, no difference was found in in vitro or in vivo growth rates, attachment to laminin or endothelial cells or cell motility through a reconstituted basement membrane. Analysis of surface membrane proteins labeled with (125)I on SDS-PAGE showed that a 29 kD band specifically bound to type IV collagen-coupled beads was more intense in ML-SN2 than in ML-MT-neo. Genistein, a protein tyrosine kinase inhibitor, dramatically reduced protein tyrosine kinase (PTK) activity of ML-SN2 in a dose-dependent fashion, corresponding to the reduction of adhesiveness to type IV collagen. The expression of the type IV collagen-binding protein (p29) of ML-SN2 was also reduced significantly by genistein treatment. These results suggested that the fyn product in Meth A cells augments the expression of a type IV collagen-binding protein through elevation of the PTK activity of the membrane fraction and thus facilitates the metastasis of Meth A.


Subject(s)
Carrier Proteins/biosynthesis , Cell Adhesion Molecules/biosynthesis , Collagen Type IV/metabolism , Fibrosarcoma/metabolism , Proto-Oncogene Proteins/physiology , Animals , Cell Movement , Female , Fibronectins/metabolism , Fibrosarcoma/pathology , Fibrosarcoma/secondary , Genistein/pharmacology , Integrin beta1/physiology , Laminin/metabolism , Lung Neoplasms/secondary , Mice , Mice, Inbred BALB C , Proto-Oncogene Proteins c-fyn , Sarcoma, Experimental/metabolism , Sarcoma, Experimental/pathology , Sarcoma, Experimental/secondary , Transfection , Tumor Cells, Cultured
14.
Clin Exp Metastasis ; 19(5): 437-44, 2002.
Article in English | MEDLINE | ID: mdl-12198772

ABSTRACT

The development of an effective antitumor immune response to control tumor growth is influenced by the tumor cell itself and/or by the tumor microenvironment. Tumor invasion and tumor cell spreading require a finely tuned regulation of the formation and loosening of adhesive contacts of tumor cells with the extracellular matrix (ECM). In our laboratory, a rat tumor cell line derived from a spontaneous rat sarcoma revealed, by flow cytometry, a high frequency of intercellular adhesion molecule-1 (ICAM-1, 70.1 +/- 8.7%) and urokinase-type plaminogen activator receptor (uPAR, 51.2 +/- 5.2%) positive cells, while a weak expression of MHC class II (IA, 2.2 +/- 0.2% and IE, 17.4 +/- 3.7%) and B7 (12.1 +/- 2.2%) antigens was detected. In our tumor experimental model, after implantation of tumor cells, visible tumor masses were present at days 5-7 with a relatively fast tumor growth until day 15 (progressive phase) followed by a suppression of the tumor growth (regressive phase). Here we present data that correlates a significant decrease in the frequency of ICAM-1 and uPAR expressing tumor cells with the appearance of tumor cells in sites distant from that of the primary tumor. In addition we describe the development of a cellular immune response which controls the tumor progression and is associated with an increase in the expression of major histocompatibility complex (MHC) class II IA antigen during tumor development. The histological examination at tumor progressive and regressive time points revealed the relevant presence of polymorphonuclear neutrophils (PMNs) evidencing colliquative necrosis in tumor growth areas. Taken together, these results support the idea that the balance between adhesive interactions, proteolytic activity and tumorigenicity may lead to a tumor invasive phenotype.


Subject(s)
Intercellular Adhesion Molecule-1/physiology , Mammary Neoplasms, Experimental/pathology , Neoplasm Proteins/deficiency , Receptors, Cell Surface/physiology , Sarcoma, Experimental/pathology , Animals , Cell Adhesion , Cell Division , Disease Progression , Female , Immunity, Cellular , Intercellular Adhesion Molecule-1/biosynthesis , Intercellular Adhesion Molecule-1/genetics , Lymphatic Metastasis , Mammary Neoplasms, Experimental/immunology , Mammary Neoplasms, Experimental/metabolism , Neoplasm Invasiveness , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Neoplasm Transplantation , Neutrophils/pathology , Phenotype , Rats , Rats, Wistar , Receptors, Cell Surface/biosynthesis , Receptors, Cell Surface/deficiency , Receptors, Cell Surface/genetics , Receptors, Urokinase Plasminogen Activator , Sarcoma, Experimental/immunology , Sarcoma, Experimental/metabolism , Sarcoma, Experimental/secondary , Splenic Neoplasms/secondary , Tumor Cells, Cultured/transplantation
15.
Int J Cancer ; 97(2): 135-41, 2002 Jan 10.
Article in English | MEDLINE | ID: mdl-11774255

ABSTRACT

Amifostine was investigated for its ability to inhibit spontaneous metastases formation using the well-characterized murine sarcoma, Sa-NH. Amifostine was administered intraperitoneally at a dose of 50 mg/kg every other day for 6 days to C3Hf/Kam mice until tumors reached an average size of 8-8.5 mm in diameter. Amifostine was again administered immediately after surgical removal of the tumor-bearing limbs by amputation, and then once more 2 days later. Twenty-one days later, animals were evaluated for the presence of spontaneously developed pulmonary metastases. Nontumor-bearing control animals were sham treated using the same dosing and surgery schedules. Treatment with amifostine appeared to slightly delay tumor growth, that is, 13 vs. 12 days for tumors to reach an average diameter of 8 mm. Amifostine reduced both the incidence of pulmonary metastases formed in experimental animals from 77% to 57% (p < 0.05), and their average number per animal from 12.8 +/- 5.4 (SEM) to 2.9 +/- 1.1 (SEM). The effect of amifostine exposure on serum levels of the angiogenesis inhibitor angiostatin was also determined using Western blot analysis. Consistent with the antimetastatic effect, exposure of animals to 50 mg/kg of amifostine resulted in a 4-fold enhanced serum level of angiostatin above control levels. This phenomenon occurred in tumor-bearing and nontumor-bearing animals. The effects of amifostine on matrix metalloproteinase (MMP) enzymatic activity was also determined using gelatin zymography. Conditioned growth medium collected from Sa-NH cells grown to confluency was exposed to various concentrations of SH, i.e., 2-[(aminopropyl)amino]ethane-thiol (WR-1065), the active thiol form of amifostine, for either 30 min or 18 hr. WR-1065, as a function of increasing dose and time, inhibited the enzymatic activities of MMP-2 and MMP-9. At a concentration and time of exposure likely to be achieved in vivo, that is, 40 microM and 30 min, MMP-2 and MMP-9 activities were reduced to between 30% and 40% of control values. Consistent with these affects, WR-1065 was also found to be effective in inhibiting the ability of Sa-NH cells to migrate through Matrigel membranes. After an 18-hr exposure under in vitro conditions, WR-1065 at concentrations of 4, 40 and 400 microM, and 4 mM, inhibited Sa-NH migration to 11%, 44%, 81% and 97% of control values, respectively. The abilities of amifostine and its active thiol WR-1065 to stimulate angiostatin production in mice, and to inhibit the MMP enzymatic activities and invasion ability of Sa-NH cells under in vitro conditions, are consistent with the observed antimetastatic effects exhibited against Sa-NH tumors growing in vivo.


Subject(s)
Amifostine/therapeutic use , Lung Neoplasms/prevention & control , Muscle Neoplasms/drug therapy , Radiation-Protective Agents/therapeutic use , Sarcoma, Experimental/prevention & control , Angiostatins , Animals , Blotting, Western , Cell Division/drug effects , Dose-Response Relationship, Drug , Lung Neoplasms/enzymology , Lung Neoplasms/secondary , Male , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Mercaptoethylamines/therapeutic use , Mice , Mice, Inbred C3H , Muscle Neoplasms/enzymology , Muscle Neoplasms/pathology , Neoplasm Invasiveness , Peptide Fragments/metabolism , Plasminogen/metabolism , Sarcoma, Experimental/enzymology , Sarcoma, Experimental/secondary , Xenograft Model Antitumor Assays
16.
Gene Ther ; 8(2): 149-56, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11313784

ABSTRACT

We have previously reported that superoxide stimulates the motility of tumor cells and the administration of Cu-Zn superoxide dismutase (SOD) significantly suppresses metastasis. However, ideally, anti-metastatic therapy should be long-lasting, systemically effective and have low toxicity. The half-life of Cu-Zn SOD in plasma is so short that it cannot provide long-lasting effects. Therefore, in this study we have developed a gene therapy in a mouse model utilizing extracellular SOD (EC-SOD), which is the most prevalent SOD isoenzyme in extracellular fluids. We retrovirally transfected fibroblasts (syngeneic) with the EC-SOD gene and established EC-SOD-secreting fibroblasts. Inoculation of EC-SOD-secreting fibroblasts suppressed both artificial and spontaneous metastatic lung nodules in mouse metastasis models. These data indicate the feasibility of anti-metastatic gene therapy utilizing the EC-SOD gene.


Subject(s)
Genetic Therapy/methods , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Superoxide Dismutase/genetics , Transduction, Genetic , Animals , Carcinoma, Lewis Lung/pathology , Carcinoma, Lewis Lung/secondary , Carcinoma, Lewis Lung/therapy , Cell Culture Techniques , Cell Division , Culture Media , DNA, Complementary/genetics , Feasibility Studies , Fibroblasts/transplantation , Gene Expression , Isoenzymes/genetics , Isoenzymes/metabolism , Lung Neoplasms/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred Strains , Neoplasm Transplantation , RNA, Messenger/genetics , Sarcoma, Experimental/pathology , Sarcoma, Experimental/secondary , Sarcoma, Experimental/therapy , Superoxide Dismutase/metabolism
17.
Cancer Res ; 61(1): 333-8, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11196183

ABSTRACT

Whereas large numbers of cells from a primary tumor may gain access to the circulation, few of them will give rise to metastases. The mechanism of elimination of these tumor cells, often termed "metastatic inefficiency," is poorly understood. In this study, we show that apoptosis in the lungs within 1-2 days of introduction of the cells is an important component of metastatic inefficiency. First, we show that death of transformed, metastatic rat embryo cells occurred via apoptosis in the lungs 24-48 h after injection into the circulation. Second, we show that Bcl-2 overexpression in these cells inhibited apoptosis in culture and also conferred resistance to apoptosis in vivo in the lungs 24-48 h after injection. This inhibition of apoptosis led to significantly more macroscopic metastases. Third, comparison between the extent of apoptosis by a poorly metastatic cell line to that by a highly metastatic cell line 24 h after injection in the lungs revealed more apoptosis by the poorly metastatic cell line. These results indicate that apoptosis, which occurs at 24-48 h after hematogenous dissemination in the lungs is an important determinant of metastatic inefficiency. Although prior work has shown an association between apoptosis in culture and metastasis in vivo, this work shows that apoptosis in vivo corresponds to decreased metastasis in vivo.


Subject(s)
Apoptosis/physiology , Lung Neoplasms/secondary , Neoplastic Cells, Circulating/pathology , Animals , Cell Line, Transformed , Cell Transformation, Neoplastic/pathology , Female , Fibroblasts/metabolism , Fibroblasts/pathology , Fibrosarcoma/metabolism , Fibrosarcoma/pathology , Fibrosarcoma/secondary , Green Fluorescent Proteins , Humans , Luminescent Proteins/metabolism , Lung Neoplasms/metabolism , Melanoma, Experimental/metabolism , Melanoma, Experimental/pathology , Melanoma, Experimental/secondary , Mice , Mice, Nude , Neoplasm Metastasis , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/physiology , Rats , Sarcoma, Experimental/metabolism , Sarcoma, Experimental/pathology , Sarcoma, Experimental/secondary
18.
Anticancer Res ; 21(6A): 3981-7, 2001.
Article in English | MEDLINE | ID: mdl-11911280

ABSTRACT

The antitumoral and immunostimulating properties of rViscumin (recombinant mistletoe lectin) were investigated in two mouse tumor models. After intravenous inoculation with RAW-117-P or L-1 sarcoma cells in Balb/c mice, rViscumin was given s.c. at non-toxic doses ranging from 0.3 to 150 ng rViscumin/kg. One set of experiments was performed to investigate the survival of rViscumin-treated animals. Another set was carried out to analyze the effect of rViscumin treatment on the number of tumor colonies in infiltrated lungs (RAW-117P) or liver (L-1) and the activation of immune cell subsets, respectively. An overall prolonged survival time after treatment with rViscumin and a reduction in the number of tumor colonies after administration of certain rViscumin doses was observed. Immunophenotyping of the peripheral leukocytes of treated mice revealed increased numbers of T-lymphocytes, pan-NK cells and activated monocytes. The results indicate that rViscumin has antineoplastic properties and might therefore be a promising candidate in cancer therapy.


Subject(s)
Adjuvants, Immunologic/pharmacology , Antineoplastic Agents/pharmacology , Plant Preparations , Plant Proteins , Sarcoma, Experimental/drug therapy , Toxins, Biological/pharmacology , Animals , Drug Screening Assays, Antitumor , Immunocompetence , Liver Neoplasms, Experimental/drug therapy , Liver Neoplasms, Experimental/immunology , Liver Neoplasms, Experimental/secondary , Lung Neoplasms/drug therapy , Lung Neoplasms/immunology , Lung Neoplasms/secondary , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/immunology , Male , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Recombinant Proteins/pharmacology , Ribosome Inactivating Proteins, Type 2 , Sarcoma, Experimental/immunology , Sarcoma, Experimental/secondary , Tumor Cells, Cultured
19.
Jpn J Cancer Res ; 91(12): 1333-8, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11123434

ABSTRACT

The antitumor efficacy of the conjugate of doxorubicin (DXR) and carboxymethylpullulan (CMPul) with Phe-Gly spacer (CMPul-FG-DXR) was evaluated using murine tumor models and compared with that of DXR. The conjugate exhibited higher antitumor efficacy against Lewis lung carcinoma than DXR. Complete tumor regression followed by long-term tumor-free survival was frequently observed when CMPul-FG-DXR was administered i.v. three times at a dose equivalent to 10 mg / kg of DXR. The superior survival as well as anti-metastatic effect of CMPul-FG-DXR in comparison with DXR was also demonstrated with the M5076 murine reticulosarcoma model. Body weight loss in mice treated with the conjugate was less than that in the DXR-treated group, indicating lower systemic toxicity of CMPul-FG-DXR. Simply mixing CMPul with DXR did not enhance the antitumor activity of DXR, showing that the conjugation of DXR with CMPul is necessary for improved antitumor activity. However, no enhanced antitumor efficacy of the conjugates was observed against a non-solid tumor model such as P388 leukemia. In summary, improved antitumor efficacy with reduced systemic toxicity of CMPul-FG-DXR was demonstrated in the present study. CMPul-FG-DXR may be useful as a cancer chemotherapy agent against solid tumors and metastases.


Subject(s)
Antineoplastic Agents/toxicity , Doxorubicin/therapeutic use , Glucans/therapeutic use , Leukemia P388/drug therapy , Liver Neoplasms/secondary , Lung Neoplasms/drug therapy , Sarcoma, Experimental/secondary , Animals , Antineoplastic Agents/therapeutic use , Body Weight/drug effects , Doxorubicin/analogs & derivatives , Doxorubicin/toxicity , Female , Glucans/toxicity , Liver/drug effects , Liver/pathology , Liver Neoplasms/prevention & control , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Inbred Strains , Organ Size/drug effects , Sarcoma, Experimental/drug therapy , Survival
20.
Clin Cancer Res ; 6(8): 3380-7, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10955826

ABSTRACT

Hepatic metastasis is a major clinical problem in cancer treatment. We examined antitumor activity of alpha-galactosylceramide (KRN7000) on mice with spontaneous liver metastases of reticulum cell sarcoma M5076 tumor cells (spontaneous metastasis model). In this model, all mice that were s.c. challenged with one million tumor cells developed a solid s.c. mass by day 7 and died of hepatic metastases. In the current study, we administered 100 microg/kg of KRN7000 to the model mice on days 7, 11, and 15. This treatment suppressed the growth of established liver metastases and resulted in the prolongation of survival time. Fluorescence-activated cell sorter analysis of phenotypes of spleen cells, hepatic lymphocytes, and regional lymph node cells around the s.c. tumor revealed that CD3+NK1.1+ (NKT) cells increased in hepatic lymphocytes of the KRN7000-treated mice. Cytotoxic activity and IFN-gamma production of hepatic lymphocytes were augmented in comparison with those of spleen cells and regional LN cells. At the same time, interleukin (IL)-12 production of hepatic lymphocytes was markedly enhanced. Neutralization of IL-12 using a blocking monoclonal antibody diminished the prolonged survival time. These results showed that the in vivo antitumor effects of KRN7000 on spontaneous liver metastases were dependent on the endogenous IL-12 production, where NKT cells in the liver are suggested to be involved. Adjuvant immunotherapy using KRN7000 could be a promising modality for the prevention of postoperative liver metastases.


Subject(s)
Antineoplastic Agents/pharmacology , Galactosylceramides/pharmacology , Interleukin-12/immunology , Liver Neoplasms, Experimental/drug therapy , Liver Neoplasms, Experimental/secondary , Sarcoma, Experimental/drug therapy , Sarcoma, Experimental/secondary , Adjuvants, Immunologic/pharmacology , Animals , Antibodies, Monoclonal/pharmacology , Cytotoxicity, Immunologic/drug effects , Female , Immunophenotyping , Interferon-gamma/biosynthesis , Interleukin-12/antagonists & inhibitors , Interleukin-12/biosynthesis , Interleukin-12/metabolism , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Liver/cytology , Liver/immunology , Liver/metabolism , Liver Neoplasms, Experimental/immunology , Lymph Nodes/cytology , Lymph Nodes/immunology , Lymphocytes/drug effects , Lymphocytes/immunology , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , Sarcoma, Experimental/immunology , Spleen/cytology , Spleen/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...